Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial

BACKGROUND: Despite the success in decreasing varicella-related disease burden, live-attenuated Oka vaccine strain of varicella-zoster virus (vOka) remains neuro-virulence and may establish latency and reactivate, raising safety concerns. Here we aimed to evaluate the safety and immunogenicity of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Zhao-Jun, Huang, Shou-Jie, Qiu, Ling-Xian, Li, Chang-Gui, Yu, Xiao-Juan, Li, Ming-Qiang, Chen, Zhen, Zhong, Guo-Hua, Pan, De-Quan, Huang, Li-Rong, Lv, Bang-Jun, Cui, Xue-Lian, Song, Qiao-Qiao, Jia, Ji-Zong, Han, Jin-Le, Wang, Wei, Zhu, Hua, Cheng, Tong, Su, Ying-Ying, Li, Yi-Min, Ye, Xiang-Zhong, Wu, Ting, Zhang, Jun, Xia, Ning-Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240365/
https://www.ncbi.nlm.nih.gov/pubmed/37283962
http://dx.doi.org/10.1016/j.lanwpc.2023.100707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240365/
https://www.ncbi.nlm.nih.gov/pubmed/37283962
http://dx.doi.org/10.1016/j.lanwpc.2023.100707

Ejemplares similares